A UK national audit of hereditary and acquired angioedema

Jolles, S., Williams, P., Carne, E., Mian, H., Huissoon, A., Wong, G., Hackett, S., Lortan, J., Platts, V., Longhurst, H., Grigoriadou, S., Dempster, J., Deacock, S., Khan, S., Darroch, J., Simon, C., Thomas, M., Pavaladurai, V., Alachkar, H., Herwadkar, A., Abinun, M., Arkwright, P., Tarzi, M., Helbert, M., Bangs, C., Pastacaldi, C., Phillips, C., Bennett, H. and El-Shanawany, T. 2014. A UK national audit of hereditary and acquired angioedema. Clinical and Experimental Immunology 175 (1) , pp. 59-67. 10.1111/cei.12159

Full text not available from this repository.

Abstract

Hereditary angioedema (HAE) and acquired angioedema (AAE) are rare life‐threatening conditions caused by deficiency of C1 inhibitor (C1INH). Both are characterized by recurrent unpredictable episodes of mucosal swelling involving three main areas: the skin, gastrointestinal tract and larynx. Swelling in the gastrointestinal tract results in abdominal pain and vomiting, while swelling in the larynx may be fatal. There are limited UK data on these patients to help improve practice and understand more clearly the burden of disease. An audit tool was designed, informed by the published UK consensus document and clinical practice, and sent to clinicians involved in the care of HAE patients through a number of national organizations. Data sets on 376 patients were received from 14 centres in England, Scotland and Wales. There were 55 deaths from HAE in 33 families, emphasizing the potentially lethal nature of this disease. These data also show that there is a significant diagnostic delay of on average 10 years for type I HAE, 18 years for type II HAE and 5 years for AAE. For HAE the average annual frequency of swellings per patient affecting the periphery was eight, abdomen 5 and airway 0·5, with wide individual variation. The impact on quality of life was rated as moderate or severe by 37% of adult patients. The audit has helped to define the burden of disease in the UK and has aided planning new treatments for UK patients.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Wiley: 12 months
ISSN:	0009-9104
Funders:	N/A
Date of Acceptance:	15 June 2013
Last Modified:	07 Jan 2019 13:31
URI:	https://orca.cardiff.ac.uk/id/eprint/117938

Citation Data

Cited 63 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item